The impact of medication belief on adherence to infliximab in patients with Crohn’s disease

The impact of medication belief on adherence to infliximab in patients with Crohn’s disease

Objective: Crohn’s disease (CD) is an incurable chronic disease that requires long-term treatment. As an anti-tumor necrosis factor (TNF) agent, Infliximab (IFX) is widely used in the treatment of Crohn’s disease, while the adherence is not high. The purpose of this study was to investigate the adhe...

Full description

Bibliographic Details
Main Authors:	Shuyan Li, Yan Ma, Hongling Sun, Zijun Ni, Shurong Hu, Yan Chen, Meijuan Lan
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-08-01
Series:	Frontiers in Pharmacology
Subjects:	adherence medication belief Crohn’s disease infliximab China
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1185026/full

Similar Items

Refractory Duodenal Crohn's Disease Successfully Treated with Infliximab
by: You Lim Kim, et al.
Published: (2014-01-01)

Early intestinal obstruction after infliximab therapy in Crohn’s disease
by: Mitsuro Chiba, et al.
Published: (2019-08-01)

Successful Treatment of Postoperative Fistula with Infliximab in a Patient with Crohn's Disease
by: Seong Yeon Jeong, et al.
Published: (2014-01-01)

Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn’s Disease
by: Luis Eduardo Miani Gomes, et al.
Published: (2019-04-01)

Long-Term Clinical Outcomes of Korean Patient With Crohn's Disease Following Early Use of Infliximab
by: Nam Hee Kim, et al.
Published: (2014-10-01)

Cortical Vein Thrombosis after Infliximab Treatment for Crohn’s Disease
by: Saeed Razmeh, et al.
Published: (2021-03-01)

Optimising infliximab induction dosing to achieve clinical remission in Chinese patients with Crohn’s disease
by: Kouzhu Zhu, et al.
Published: (2024-08-01)

Comparison of Long-term Outcomes of Infliximab versus Adalimumab in 1,488 Biologic-Naive Korean Patients with Crohn’s Disease
by: Yoon Suk Jung, et al.
Published: (2021-01-01)

Loss of Response to Long-Term Infliximab Therapy in Children with Crohn’s Disease
by: George Alex, et al.
Published: (2013-10-01)

Infliximab‐induced seizures in a patient with Crohn’s disease: a case report
by: Zhijie Lv, et al.
Published: (2021-04-01)

Predictors of response to infliximab in patients with fistulizing Crohn's disease Factores predictivos de respuesta a infliximab en pacientes con enfermedad de Crohn fistulizante
by: M. Luna-Chadid, et al.
Published: (2004-06-01)

Efficacy of Infliximab for the Treatment of Oral Manifestation of Crohn’s Disease
by: Aibar Aginbay, et al.
Published: (2022-11-01)

Prognostic factors for the efficacy of infliximab in patients with luminal fistulizing Crohn’s disease
by: Ye Ma, et al.
Published: (2023-03-01)

Adherence patterns in naïve and prevalent use of infliximab and its biosimilar
by: Chibuike J. Alanaeme, et al.
Published: (2022-11-01)

Treatment persistence during therapeutic sequences with adalimumab and infliximab in the treatment of Crohn's disease
by: Carlos Taxonera, et al.

MRI-Based Radiomic Signature Identifying Secondary Loss of Response to Infliximab in Crohn's Disease
by: Jing Feng, et al.
Published: (2022-01-01)

Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn’s disease
by: Matsumoto S, et al.
Published: (2018-07-01)

Fecal Calprotectin at Postinduction Is Capable of Predicting Persistent Remission and Endoscopic Healing after 1 Year of Treatment with Infliximab in Pediatric Patients with Crohn’s Disease
by: Yoo Min Lee, et al.
Published: (2024-05-01)

Co-existence of relapsing polychondritis and Crohn disease treated successfully with infliximab
by: Hye-In Jung, et al.
Published: (2021-01-01)

The Association Between Genetic Variants, Pharmacokinetics, and Infliximab Efficacy in Pediatric Patients With Crohn's Disease in China
by: Wenhui Hu, et al.
Published: (2021-12-01)

Clinical efficacy of adalimumab versus infliximab and the factors associated with recurrence or aggravation during treatment of anal fistulas in Crohn's disease
by: Cheng-Chun Ji, et al.
Published: (2017-04-01)

Cytokine Profile at Diagnosis Affecting Trough Concentration of Infliximab in Pediatric Crohn’s Disease
by: Yiyoung Kwon, et al.
Published: (2022-09-01)

ADALIMUMAB INDUCTION AND MAINTAINING REMISSION FOR CROHN’S DISEASE IN PATIENT WHO LOST RESPONSE TO INFLIXIMAB. Case report
by: Ivaylo Vazharov, et al.
Published: (2016-12-01)

Infliximab for Anoperineal Lesions in Crohn's Disease: Remission Appears to be Based on Rapid Combination Therapy at High Doses
by: Nadia Fathallah, et al.
Published: (2022-06-01)

Efficacy of adalimumab in patients with crohn's disease and failure to infliximab therapy: a clinical series Eficacia de Adalimumab en pacientes con enfermedad de Crohn y fracaso previo a la terapia con Infliximab: resultados de una serie clínica
by: Patricia Cordero-Ruiz, et al.
Published: (2011-06-01)

Evaluation of Infliximab Effects on Gastrointestinal Bleeding in Crohn’s Disease Using Double-Balloon Endoscopy
by: Manzurul Chowdhury, et al.
Published: (2009-07-01)

CORRELATION BETWEEN TROUGH LEVELS OF INFLIXIMAB AND POSTOPERATIVE ENDOSCOPIC RECURRENCE IN CROHN’S DISEASE PATIENTS SUBMITTED TO ILEOCOLONIC RESECTIONS: A SYSTEMATIC REVIEW
by: Fernanda da Silva Barbosa BARAÚNA, et al.
Published: (2021-04-01)

Erythema dyschromicum perstans (ashy dermatosis) during the treatment with infliximab in a child with Crohn disease
by: Michał Sobjanek, et al.
Published: (2014-03-01)

Infliximab- and Immunosuppressant-Resistant Crohn’s Disease Successfully Treated with Adsorptive Granulocyte Apheresis Combined with Prednisolone
by: Munenori Itagaki, et al.
Published: (2012-02-01)

A novel role of the splenic volume in Crohn’s disease: evaluating the efficacy of infliximab
by: Xuan Shi, et al.
Published: (2023-08-01)

Infliximab-induced psoriasis in a patient with crohn′s disease
by: Iqbal Bukhari, et al.
Published: (2015-01-01)

The Combination of Predictive Factors of Pharmacokinetic Origin Associates with Enhanced Disease Control during Treatment of Pediatric Crohn’s Disease with Infliximab
by: Marla C. Dubinsky, et al.
Published: (2023-09-01)

Combined therapy with early initiation of infliximab following drainage of perianal fistulising Crohn’s disease: a retrospective cohort study
by: Ping Zhu, et al.
Published: (2022-01-01)

The role of proactive therapeutic drug monitoring in guiding infliximab therapeutic optimization in pediatric patients with Crohn's disease: A retrospective study
by: Junya Song, et al.
Published: (2024-12-01)

Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn’s Disease Comparing, between CT-P13 and Originator Infliximab
by: Jihye Park, et al.
Published: (2023-05-01)

Tracing the historical foundations of infliximab in Crohn’s disease treatment: a cited reference analysis
by: Andy Wai Kan Yeung
Published: (2024-11-01)

A novel role of prognostic nutritional index in predicting the effectiveness of infliximab in Crohn's disease
by: Ziheng Peng, et al.
Published: (2023-12-01)

Medication Belief is Associated with Improved Adherence to Exclusive Enteral Nutrition in Patients with Crohn’s Disease
by: Li S, et al.
Published: (2021-10-01)

Infliximab trough levels are associated with endoscopic healing but not with transmural healing at one year treatment with infliximab in pediatric patients with Crohn’s disease
by: So Yoon Choi, et al.
Published: (2023-06-01)

Development and validation of a clinical radiomics nomogram to predict secondary loss of response to infliximab in Crohn's disease patients
by: Chao Zhu, et al.
Published: (2023-04-01)